BioRestorative Therapies, Inc.

BRTX | $1.39 -3.47% -3.6% 160K

(0.0% 1d) (3.0% 1m) (-64.9% 1y) (0.0% 2d) (0.0% 3d) (5.4% 7d) (-86.53% volume)
Earnings Calendar:
Market Cap: $ 9,410,187
http://www.biorestorative.com/
Sec Filling | Patents | 5 employees

(US) biorestorative therapies, inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • disc/spine program (brtxdisc™): our lead cell therapy candidate, brtx-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. we intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. the brtx-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. in an outpatient procedure, brtx-100 is to be injected by a physician into the patient’s damaged disc. the treatment is intended for patients whose pain has not been alleviated by non-invas

injection t-cell

add to watch list Paper trade email alert is off

Press-releases

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
BRTX | $1.39 -3.47% -3.6% 160K

Professional, Scientific, and T...

| 5.38% | O: 9.23% H: 15.49% C: -7.75%
brtx-100 fda clearance study

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
BRTX | $1.39 -3.47% -3.6% 160K

Professional, Scientific, and T...

| 3.01% | O: -1.5% H: 0.0% C: -2.29%
brtx-100 disease trial

BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants
Published: 2024-04-03 (Crawled : 21:00) - globenewswire.com
BRTX | $1.39 -3.47% -3.6% 160K

Professional, Scientific, and T...

| 4.58% | O: 2.29% H: 1.49% C: 0.0%

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
BRTX | $1.39 -3.47% -3.6% 160K

Professional, Scientific, and T...

| -0.72% | O: -2.17% H: 3.71% C: 3.7%
report

BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
Published: 2024-03-11 (Crawled : 20:00) - globenewswire.com
BRTX | $1.39 -3.47% -3.6% 160K

Professional, Scientific, and T...

| 7.03% | O: 3.13% H: 1.14% C: 0.0%
conference

BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market
Published: 2024-02-06 (Crawled : 13:00) - globenewswire.com
BRTX | $1.39 -3.47% -3.6% 160K

Professional, Scientific, and T...

| -60.29% | O: -55.07% H: 6.45% C: 1.29%
million

BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
Published: 2024-02-05 (Crawled : 12:30) - globenewswire.com
BRTX | $1.39 -3.47% -3.6% 160K

Professional, Scientific, and T...

| -51.07% | O: 14.64% H: 14.33% C: 7.48%
brtx-100 disease study

BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting
Published: 2024-02-01 (Crawled : 12:30) - globenewswire.com
BRTX | $1.39 -3.47% -3.6% 160K

Professional, Scientific, and T...

| -15.95% | O: 7.98% H: 35.69% C: 22.73%
brtx-100 research meeting

BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program
Published: 2023-12-12 (Crawled : 14:00) - globenewswire.com
BRTX | $1.39 -3.47% -3.6% 160K

Professional, Scientific, and T...

| -21.26% | O: 10.34% H: 3.65% C: -4.17%
obesity patent application program

BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City
Published: 2023-10-09 (Crawled : 16:00) - globenewswire.com
BRTX | $1.39 -3.47% -3.6% 160K

Professional, Scientific, and T...

| -35.68% | O: 0.0% H: 1.88% C: 0.94%
conference city

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001021771-24-000056	4	2024-02-15	2024-02-13	Buy	A	79646	79646
0001021771-24-000054	4	2024-02-15	2024-02-13	Buy	A	79646	79646